An Indian pharma company just wrote history's biggest cheque for a US drugmaker — and shareholders just said yes.
Organon's shareholders have approved Sun Pharma's $11.75 billion buyout.
All-cash. $14 a share.
Organon now becomes a wholly owned subsidiary of Sun Pharma's US arm.
Deal's not closed yet — regulators still have to sign off. But the hardest room to convince just gave a standing nod.
This isn't just Sun Pharma's biggest deal ever.
It's the largest overseas acquisition by any Indian pharmaceutical company, ever.
Bigger than anything Sun, Dr Reddy's, or Cipla have pulled off on foreign soil.
And it's the largest biopharma deal of 2026, period — anywhere in the world.
Organon isn't a random target. It was spun out of Merck back in 2021 — carrying Merck's women's health and legacy medicine portfolio out the door with it.
Since then, it's built out:
Buy that, and you don't just get revenue. You get a seat at the top table.
That's not incremental growth. That's a company buying its way up multiple league tables in one move.
For years, Indian pharma was known as the world's generics factory — cheap, high-volume, low-glamour.
This deal flips that script.
Sun Pharma isn't just manufacturing someone else's molecule anymore.
It's now the owner of a global specialty portfolio, sitting inside American healthcare, competing on Merck's old turf.
Shareholders have voted. Regulators are next.
If this clears, Indian pharma just changed weight classes.
That's all for now!
